Natrum Arsenicicum

Sodium Arsenate, Dibasic, Heptahydrate is a standardized chemical allergen and allergenic extract used primarily in diagnostic skin testing to identify hypersensitivity reactions. It belongs to the class of Non-Standardized Food and Chemical Allergenic Extracts.

Dosage for Sodium Arsenate, Dibasic, Heptahydrate is strictly individualized and depends entirely on the method of administration and the patient's prior history of allergic reactions.

• Skin Prick Testing (SPT): Typically, one drop of a highly diluted extract (e.g., 1:100 or 1:1000 w/v) is applied to the forearm or back, followed by a superficial puncture of the skin.
• Intradermal Testing: If the SPT is negative but suspicion remains high, a healthcare provider may inject 0.02 mL to 0.05 mL of a more dilute solution (e.g., 1:1000 to 1:10,000 w/v) into the dermis.
• Patch Testing: A standardized concentration (often 1% in petrolatum or a specific microgram amount per cm²) is applied via an adhesive patch and left in place for 48 hours.

Sodium Arsenate, Dibasic, Heptahydrate may be used in pediatric populations under the strict supervision of a pediatric allergist. Dosing is generally similar to adult diagnostic dosing, but the number of simultaneous tests may be limited to reduce the risk of systemic reactions and patient discomfort. Safety and efficacy in infants under the age of 2 have not been extensively established for this specific allergen.

Renal Impairment

No specific dose adjustments are required for diagnostic skin testing in patients with renal impairment, as the systemic exposure is negligible. However, patients with end-stage renal disease should be monitored closely for skin reactivity, as uremia can sometimes suppress skin test responses.

Hepatic Impairment

No dosage adjustments are necessary for hepatic impairment due to the minimal systemic absorption of the allergenic extract.

Elderly Patients

Elderly patients may exhibit reduced skin reactivity (smaller wheal and flare responses) due to age-related changes in skin elasticity and mast cell density. Healthcare providers may need to interpret results with caution but generally do not adjust the concentration of the extract.

This medication is never self-administered. It must be administered by a trained healthcare professional in a medical facility.

1. 1Preparation: The skin (usually the forearm or back) is cleaned with alcohol.
2. 2Application: The extract is applied via the chosen method (prick, intradermal, or patch).
3. 3Observation: For prick and intradermal tests, the patient must remain in the clinic for at least 30 minutes to be monitored for signs of a systemic allergic reaction (anaphylaxis).
4. 4Storage: The extract must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F) to maintain its potency. It should never be frozen.

As this is a diagnostic test or a scheduled clinical treatment, a 'missed dose' typically refers to a missed appointment. If an appointment for testing or immunotherapy is missed, contact your allergist immediately to reschedule. In immunotherapy, missing a dose may require a temporary reduction in the concentration of the next dose to ensure safety.

An overdose of Sodium Arsenate, Dibasic, Heptahydrate in a clinical setting would manifest as an exaggerated local reaction (large, painful swelling) or a systemic allergic reaction.

• Symptoms: Hives, swelling of the throat, wheezing, rapid pulse, or a drop in blood pressure.
• Emergency Measures: Immediate administration of epinephrine (EpiPen), antihistamines, and corticosteroids. In the extremely unlikely event of systemic arsenic poisoning from a massive procedural error, chelation therapy would be considered.

> Important: Follow your healthcare provider's dosing and scheduling instructions exactly. Do not attempt to use allergenic extracts outside of a professional medical environment.

Because Sodium Arsenate, Dibasic, Heptahydrate is designed to provoke an immune response, 'side effects' at the site of application are often expected and indicate a positive test result.

• Local Redness (Erythema): A reddening of the skin around the test site. This typically appears within 15-20 minutes for prick tests and 48-72 hours for patch tests.
• Itching (Pruritus): An intense itching sensation at the site of application. This is a direct result of histamine release.
• Wheal Formation: A raised, white or pale bump (similar to a mosquito bite) that appears shortly after prick testing. This usually subsides within 2 to 4 hours.

Sodium Arsenate, Dibasic, Heptahydrate is a potent biological and chemical agent. It must only be used for diagnostic or therapeutic purposes under the direct supervision of a qualified medical professional. Patients should be aware that the primary risk associated with this substance is an unpredictable systemic allergic reaction.

According to the FDA-approved labeling for allergenic extracts, these products must be used with extreme caution.

• Risk of Anaphylaxis: There is a constant risk of systemic reactions, which can be fatal.
• Supervision: Administration must occur in a setting where emergency resuscitative equipment and trained personnel are available.
• Patient Stability: Testing should not be performed on patients with unstable asthma or those who have recently experienced a severe allergic reaction to other substances.

There are few absolute contraindications regarding drug-drug interactions, but certain medications make the management of a reaction much more difficult:

• Beta-Blockers (e.g., Propranolol, Metoprolol): These medications can block the effects of epinephrine. If a patient on a beta-blocker has an anaphylactic reaction to Sodium Arsenate, the standard rescue treatment (epinephrine) may be ineffective, potentially leading to a fatal outcome. This is a critical safety consideration.

• ACE Inhibitors (e.g., Lisinopril): These may increase the risk of severe systemic reactions or angioedema during allergy testing.
• MAO Inhibitors (e.g., Phenelzine): These can interfere with the body's ability to process sympathetic nervous system triggers, complicating the treatment of an allergic reaction.

Sodium Arsenate, Dibasic, Heptahydrate must NEVER be used in the following circumstances:

• Previous Severe Anaphylaxis: If a patient has a known history of life-threatening anaphylaxis specifically to arsenic compounds, further skin testing is generally contraindicated as the risk outweighs the diagnostic benefit.
• Acute Systemic Illness: Testing should not be performed if the patient has a fever, acute infection, or is in the midst of a severe asthma exacerbation. The immune system is already compromised, increasing the risk of a systemic reaction.
• Unstable Cardiovascular Disease: Patients with unstable angina or recent myocardial infarction should not undergo testing, as the stress of a potential allergic reaction (or the epinephrine used to treat it) could be fatal.

Sodium Arsenate, Dibasic, Heptahydrate is generally classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. While the amount of arsenic absorbed during a skin test is negligible, the primary risk to the fetus is maternal anaphylaxis, which can lead to hypoxia (lack of oxygen) for the baby. Most allergists recommend delaying elective diagnostic skin testing until after the first trimester, or more commonly, until after delivery.

It is not known whether the minute amounts of arsenic from a diagnostic test are excreted in human milk. However, given the extremely low dose and poor systemic bioavailability from skin testing, the risk to a nursing infant is considered clinically insignificant. Breastfeeding mothers should consult their doctor, but generally, testing is considered safe during lactation.

Skin testing with Sodium Arsenate, Dibasic, Heptahydrate is permissible in children, but it must be performed by a pediatric allergy specialist. Children may be more distressed by the testing procedure, and their skin may be more reactive. The 'back' is the preferred site for testing in small children to prevent them from interfering with the test sites.

Sodium Arsenate, Dibasic, Heptahydrate acts as a specific antigen. In the context of Type I Hypersensitivity, it functions by cross-linking allergen-specific IgE antibodies on the surface of mast cells and basophils. This cross-linking triggers a signal transduction pathway involving tyrosine kinases, leading to an influx of calcium ions and the subsequent exocytosis of pre-formed mediators (histamine, proteases).

In Type IV Hypersensitivity, the arsenic ions act as haptens. They bind to endogenous proteins in the skin to form a complete antigen. This complex is processed by Langerhans cells (antigen-presenting cells in the skin) and presented to T-lymphocytes. In sensitized individuals, this leads to T-cell activation, cytokine release (such as IFN-gamma and IL-2), and the recruitment of macrophages, resulting in the localized inflammatory response seen in patch testing.

• Onset of Effect: For IgE-mediated responses (prick test), the onset is rapid, typically 10-20 minutes. For cell-mediated responses (patch test), the onset is delayed, typically 48-72 hours.